Overview
About PeptiDream Inc.
Our vision and mission at PeptiDream is to revolutionize drug discovery by discovering the next generation of transformational therapeutics and diagnostics that will lead to a healthier tomorrow for patients worldwide.
With our proprietary PDPS (Peptide Discovery Platform System) technology, one of the world’s most advanced drug discovery platforms, at our core, we have grown from a small university startup into one of the largest biotech companies in Japan, with a global reputation as the leading peptide discovery company. Along the way we have greatly expanded our R&D capabilities, made and continue to witness exceptional technological breakthroughs, while expanding the uses of peptides across a growing variety of modalities, such as peptide-drug conjugates (PDCs) and multi-functional peptide conjugates (MPCs), and allowing us to create an ever-growing pipeline of innovative therapeutic and diagnostic programs, which we continue to partner out to a wide range of companies for clinical development and commercialization. The integration of PDRadiopharma represents a further extension of these efforts, positioning us to transform the field of targeted-radiopharmaceuticals.
With our proprietary PDPS (Peptide Discovery Platform System) technology, one of the world’s most advanced drug discovery platforms, at our core, we have grown from a small university startup into one of the largest biotech companies in Japan, with a global reputation as the leading peptide discovery company. Along the way we have greatly expanded our R&D capabilities, made and continue to witness exceptional technological breakthroughs, while expanding the uses of peptides across a growing variety of modalities, such as peptide-drug conjugates (PDCs) and multi-functional peptide conjugates (MPCs), and allowing us to create an ever-growing pipeline of innovative therapeutic and diagnostic programs, which we continue to partner out to a wide range of companies for clinical development and commercialization. The integration of PDRadiopharma represents a further extension of these efforts, positioning us to transform the field of targeted-radiopharmaceuticals.